
Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease
Keywords: bioresorbable scaffold; coronary artery disease; percutaneous coronary intervention; BRS; bioresorbable scaffold(s); DAPT; dual-antiplatelet therapy; DES; drug-eluting metal stent(s); eBRS; everolimus-eluting bioresorbable scaffold(s); MACE; major adverse